ArticleMalaria journal2025
Overcoming practical challenges to pilot Sierra Leone's first school-based distribution of piperonyl butoxide-synergist ITNs: findings from a 2023 assessment in Kono district.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous distribution of insecticide treated nets (ITNs) through schools is increasingly utilized by National Malaria Programmes across sub-Saharan Africa to maintain coverage between three-year mass distribution campaigns. In March 2023, the Sierra Leone National Malaria Control Programme (NMCP) piloted its first school-based distribution (SBD) in Kono district, reaching 88,605 pupils in 531 schools with piperonyl butoxide-synergist (PBO) ITNs. The pilot was assessed to determine changes in household and population ITN access and use, and to identify areas where future widescale SBD campaigns in Sierra Leone can be improved.
methodsThis was a mixed methods assessment. A cluster, multi-stage sampled household survey was conducted across 950 households, stratified post-hoc by presence (or not) of children eligible for SBD and powered to determine significant differences in ITN access among 'intervention' households (those with at least one eligible child) and 'control' households (those with no eligible children). Key informant interviews (KIIs) were conducted with 26 SBD stakeholders representing government, donors, third party logistics agencies and implementing partners.
resultsOne- to two-months post SBD, a significantly higher proportion of households in the intervention group owned at least one ITN (93% versus 69%, p < 0.001) and at least one ITN per two people (42% versus 24%, p < 0.001). Population ITN access was significantly higher in the intervention group than the control group (69% versus 46%, p < 0.001). A higher proportion of the population also reported using an ITN the previous night in the intervention group (71%) than the control group (49%) (p < 0.001). KIIs highlighted resolvable challenges, particularly those related to untimely or insufficient funding, which led to subsequent issues for coordination, storage, transportation, quantification, distribution, training, microplanning and supervision.
conclusionSierra Leone's SBD pilot significantly improved key ITN ownership, use and access indicators at the household and population levels in Kono district one- to two-months post-SBD. However, intervention population ITN use, and access were still below the NMCP's 80% target. Gaps should be addressed for SBD scale-up. Research on costing, sustained levels of ITN use and access, and the effect of SBD ITNs on malaria parasitaemia may be considered by the NMCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.